Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics Ltd (ADR) (ADXN)
:ADXN
Total Valuation
Addex Therapeutics has a market cap or net worth of $14.45M. The enterprise value is $3.05M.
Market Cap$14.45M
Enterprise Value$3.05M
Share Statistics
Addex Therapeutics has 1,536,287 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,536,287
Owned by Insiders―
Owned by Institutions0.07%
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is -27.88%.
Return on Equity (ROE)0.73
Return on Assets (ROA)0.66
Return on Invested Capital (ROIC)-27.88%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee202.05K
Profits Per Employee3.53M
Employee Count2
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is 0.74. Addex Therapeutics’s PEG ratio is 0.02.
PE Ratio0.74
PS Ratio0.00
PB Ratio0.70
Price to Fair Value0.54
Price to FCF-1.54
Price to Operating Cash Flow-1.54
PEG Ratio0.02
Income Statement
In the last 12 months, Addex Therapeutics had revenue of 404.10K and earned 7.06M in profits. Earnings per share was 8.40.
Revenue404.10K
Gross Profit-444.26K
Operating Income-2.76M
Pretax Income-4.91M
Net Income7.06M
EBITDA-4.65M
Earnings Per Share (EPS)8.40
Cash Flow
In the last 12 months, operating cash flow was -5.37M and capital expenditures -1.27K, giving a free cash flow of -5.37M billion.
Operating Cash Flow-5.37M
Free Cash Flow-5.37M
Free Cash Flow per Share-3.50
Dividends & Yields
Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.21
52-Week Price Change12.16%
50-Day Moving Average8.36
200-Day Moving Average8.41
Relative Strength Index (RSI)55.42
Average Volume (3m)10.50K
Important Dates
Addex Therapeutics upcoming earnings date is Sep 1, 2025, TBA (Confirmed).
Last Earnings DateJun 19, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend Date―
Financial Position
Addex Therapeutics as a current ratio of 4.42, with Debt / Equity ratio of 0.48%
Current Ratio4.42
Quick Ratio4.42
Debt to Market Cap0.00
Net Debt to EBITDA0.71
Interest Coverage Ratio-776.78
Taxes
In the past 12 months, Addex Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -133.48, with an EV/FCF ratio of -115.38.
EV to Sales1.53K
EV to EBITDA-133.48
EV to Free Cash Flow-115.38
EV to Operating Cash Flow-115.40
Balance Sheet
Addex Therapeutics has $3.35M in cash and marketable securities with CHF41.99K in debt, giving a net cash position of -$3.31M billion.
Cash & Marketable Securities$3.35M
Total DebtCHF41.99K
Net Cash-$3.31M
Net Cash Per Share-$2.15
Tangible Book Value Per Share$0.10
Margins
Gross margin is 100.00%, with operating margin of -681.82%, and net profit margin of 1746.04%.
Gross Margin100.00%
Operating Margin-681.82%
Pretax Margin-1214.88%
Net Profit Margin1746.04%
EBITDA Margin-1149.63%
EBIT Margin-1214.00%
Analyst Forecast
The average price target for Addex Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-82.24%
EPS Growth Forecast―